Elon Musk’s company Neuralink has obtained clearance from the U.S. Food and Drug Administration (FDA) for its initial clinical trial involving humans, which is a significant achievement for the brain-implant startup.

Neuralink expressed its appreciation for the FDA’s approval in a tweet, stating that it is an important first step towards using their technology to assist numerous individuals in the future. The tweet, however, did not reveal any specifics about the planned study. Neuralink also clarified that it is not currently recruiting participants for the trial and promised to release more information soon. The FDA confirmed that it has granted Neuralink permission to conduct trials on patients using its brain implant and surgical robot. However, the agency declined to provide further details in its statement.